Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kissei Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円60,806 Mil.
Kissei Pharmaceutical Co's quarterly Other Stockholders Equity
increased
from Sep. 2025 (円45,546 Mil) to Dec. 2025 (円49,817 Mil) and
increased
from Dec. 2025 (円49,817 Mil) to Mar. 2026 (円60,806 Mil).
Kissei Pharmaceutical Co's annual Other Stockholders Equity
declined
from Mar. 2024 (円57,344 Mil) to Mar. 2025 (円43,453 Mil) but then
increased
from Mar. 2025 (円43,453 Mil) to Mar. 2026 (円60,806 Mil).
Kissei Pharmaceutical Co Other Stockholders Equity Related Terms
Kissei Pharmaceutical Co Other Stockholders Equity Historical Data
* Premium members only.
The historical data trend for Kissei Pharmaceutical Co's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kissei Pharmaceutical Co Other Stockholders Equity Chart
What does a Other Stockholders Equity of 円60,806 Mil mean?
Kissei Pharmaceutical Co (TSE:4547) has a Other Stockholders Equity of 円60,806 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Kissei Pharmaceutical Co and its competitors.
Is Kissei Pharmaceutical Co's Other Stockholders Equity too high?
Kissei Pharmaceutical Co's current Other Stockholders Equity is 円60,806 Mil. Overall, Kissei Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kissei Pharmaceutical Co's Other Stockholders Equity compare to ZTS?
Kissei Pharmaceutical Co's Other Stockholders Equity of 円60,806 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Kissei Pharmaceutical Co and its competitors. Kissei Pharmaceutical Co's current Other Stockholders Equity is 円60,806 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kissei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co (TSE:4547) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,688.48, compared to a current price of 円3,860.00 — trading 17.7% below its estimated fair value. The current Other Stockholders Equity is 円60,806 Mil. Kissei Pharmaceutical Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Kissei Pharmaceutical Co (TSE:4547), the current Other Stockholders Equity is 円60,806 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kissei Pharmaceutical Co (TSE:4547) Overvalued in 2026?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円3,860.00 is trading 17.7% below its estimated GF Value™ of 円4,688.48.
GuruFocus considers Kissei Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4547:
Other Stockholders Equity: 円60,806 Mil
GF Value™: 円4,688.48 vs. price of 円3,860.00 (17.7% below fair value)
No single metric tells the full story. See the TSE:4547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
79GF Score
Get the complete analysis for TSE:4547
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4547 has been successfully added to your 
